Skip to content

Immunovant, Inc. IMVT Shares (Basic)

Shares (Basic) at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
2.4B+0.1%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
1B+20.4%
Summit Therapeutics logo
Summit TherapeuticsSMMT
775.5M+5.1%
TG Therapeutics logo
TG TherapeuticsTGTX
144.4M-1.5%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfSharesOutstandingBasic.

The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s shares (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunovant, Inc.'s shares (basic)?
Immunovant, Inc. (IMVT) reported shares (basic) of 182.4M in Q1 2026.
How has Immunovant, Inc.'s shares (basic) changed year-over-year?
Immunovant, Inc.'s shares (basic) increased by 20.4% year-over-year, from 151.6M to 182.4M.
What is the long-term trend for Immunovant, Inc.'s shares (basic)?
Over 4 years (2022 to 2026), Immunovant, Inc.'s shares (basic) has grown at a 13.2% compound annual growth rate (CAGR), from 431.8M to 708.5M.
What does shares (basic) mean?
The time-weighted average number of common shares outstanding during the period, used as the denominator for basic EPS calculations.